- Home
- / Prevail Therapeutics
Prevail Therapeutics
Stock Price
$23
2021-01-26
Market Capitalization
$787.7 M
2021-01-26
Prevail Therapeutics Summary
Company Summary
- Overview
- Prevail Therapeutics is a biotech company that is developing therapeutics for neurodegenerative disorders, such as Parkinson's disease. It establishes a pipeline of programs that includes discovery-phase and preclinical development efforts.
- Type
- Public
- Status
- Active
- Founded
- 2017
- HQ
- New York, NY, US | view all locations
- Cybersecurity rating
Table of Contents
Key People
Jeffrey Sevigny, Chief Medical Officer
Mansuo Lu Shannon, Chief Scientific Officer
LocationsView all
1 location detected
New York, NY HQ
United States
430 E 29th St #940
Prevail Therapeutics Financials
Summary Financials
- Net income (Q3, 2020)
- ($18.6M)
- Cash (Q3, 2020)
- $81.7M
- EBIT (Q3, 2020)
- ($18.6M)
- Enterprise value
- $716.3M